Profile data is unavailable for this security.
About the company
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
- Revenue in USD (TTM)0.00
- Net income in USD-2.45bn
- Incorporated2015
- Employees159.00
- LocationVor Biopharma Inc500 Boylston Street, Suite 1350BOSTON 02116United StatesUSA
- Phone+1 (617) 655-6580
- Fax+1 (302) 655-5049
- Websitehttps://www.vorbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 392.66m | 27.00 | -- | 7.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 394.49m | 19.00 | -- | 3.27 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 401.60m | 73.00 | -- | 2.20 | -- | 10.80 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 409.41m | 104.00 | 21.11 | 5.78 | 19.31 | 3.28 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 415.32m | 129.00 | -- | 2.10 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 417.77m | 30.00 | -- | 3.41 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 212.07m | -84.20m | 427.27m | 368.00 | -- | 0.9169 | -- | 2.01 | -1.43 | -1.43 | 3.61 | 7.89 | 0.3403 | 6.46 | 4.55 | 576,288.10 | -13.51 | 1.56 | -16.20 | 1.80 | 94.44 | 91.45 | -39.70 | 3.99 | 3.10 | -- | 0.011 | 0.00 | 3.18 | -2.64 | -853.29 | -- | -13.62 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 427.85m | 51.00 | -- | 1.60 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 427.96m | 227.00 | -- | 1.06 | -- | 3,566.30 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 431.95m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Ocugen Inc | 5.37m | -64.02m | 436.09m | 95.00 | -- | 117.57 | -- | 81.21 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 437.12m | 42.00 | -- | -- | -- | 24.98 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 438.35m | 76.00 | -- | 3.44 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 449.48m | 163.00 | -- | 1.52 | -- | 38.14 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 470.84m | 869.00 | -- | 1.85 | 98.34 | 1.01 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
Data as of Feb 06 2026. Currency figures normalised to Vor Biopharma Inc's reporting currency: US Dollar USD
40.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 18 Dec 2025 | 5.40m | 13.96% |
| Paradigm BioCapital Advisors LPas of 11 Nov 2025 | 1.75m | 4.52% |
| Great Point Partners LLCas of 10 Dec 2025 | 1.23m | 18.05% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 669.84k | 1.73% |
| UBS Securities LLCas of 31 Dec 2025 | 245.22k | 0.63% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 232.96k | 0.60% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 93.84k | 0.24% |
| Tang Capital Management LLCas of 30 Sep 2025 | 50.00k | 0.13% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 46.90k | 0.12% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 34.33k | 0.09% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
